Durysta — Finite-Lived Intangible Assets, Net
Products & Services · Finite-Lived Intangible Assets, NetAnalysis
StatementSegment
CategoryEfficiency
SignalHigher is better
VolatilityStable
First reportedQ3 2025
Last reportedQ3 2025
How to read this metric
A steady or growing net value indicates ongoing investment and product longevity, whereas a rapid decline suggests aggressive amortization or potential asset impairment.
Detailed definition
This metric represents the net book value of the Durysta product line's finite-lived intangible assets after accounting...
Peer comparison
Comparable to 'Net Intangible Assets' or 'Product Rights, Net' found in the balance sheet notes of peer pharmaceutical firms with acquired drug portfolios.
Metric ID:
abbv_segment_durysta_finite_lived_intangible_assets_netHistorical Data
1 periods
| Q3 '25 | |
|---|---|
| Value | $711.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's durysta — finite-lived intangible assets, net?
- AbbVie (ABBV) reported durysta — finite-lived intangible assets, net of $711.00M in Q3 2025.
- What does durysta — finite-lived intangible assets, net mean?
- The remaining book value of the Durysta product's intellectual property after accounting for its usage and wear over time.